Crixivan
Product Images NDC 53808-0661

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Crixivan (NDC 53808-0661). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label (400 mg)

Description: Crixivan is a prescription-only medication in the form of 400mg capsules. Each package contains 30 capsules and is produced by Merck & Co. The lot number of the medication is 88L008U and the DO lot number is KOS0T2040C4. The expiration date of the medication is November 30th, 2010. The medication was packaged by DOH Central Pharmacy located in Tallahassee, FL 32304. The UPC number for this medication is 30006073408.*

FDA Label Image

Structural Formula (C8e77806 79bf 4d9b 8314 F449c653d87c 01)

FDA Label Image

Indinavir Protocol Figure 1 (C8e77806 79bf 4d9b 8314 F449c653d87c 02)

This appears to be a table displaying the number of patients on different drug regimens ('IDV+ZDV+L' and 'ZDV+L') at different points in time ('Study Week') and the total number of patients in each group ('N'). However, without additional context, it's difficult to provide a more detailed description or interpretation of the data.*

FDA Label Image

Cd4 Cell Counts Figure 2 (Study ACTG 320)

This is a table of study results comparing two different HIV medication combinations. The first combination includes Indinavir, Zidovudine, and Lamivudine (marked as IDV+ZDV+L) while the second combination includes only Zidovudine and Lamivudine (marked as Zov+L). The table shows the number of subjects in each group at different study weeks. However, without further context or information, it is difficult to draw any conclusions or provide a specific description.*

FDA Label Image

Indinavir Protocol 028 Figure 3 (C8e77806 79bf 4d9b 8314 F449c653d87c 04)

This table shows the proportion of patients who were given different treatments (1DV+ZDV, bV, and oV) with Indinavir and Zidovudine for the duration of 48 weeks. The data is presented for different study weeks (0, 5, 12, 24, 36, and 48) and sample sizes (N) for each treatment group are also provided.*

FDA Label Image

Indinavir Protocol 028 Figure 4 (C8e77806 79bf 4d9b 8314 F449c653d87c 05)

This appears to be a table that displays the results of a study involving three groups of participants who were administered medication. The first group was given Indinavir and Zidovudine together, the second group was given Indinavir only, and the third group was given Zidovudine only. The numbers in the table likely represent the number of participants in each group and the effectiveness of the treatment in terms of reducing the viral load of HIV over a 24-week period.*

FDA Label Image

Indinavir Protocol 035 Figure 5 (C8e77806 79bf 4d9b 8314 F449c653d87c 06)

FDA Label Image

Indinavir Protocol 035 Figure 6 (C8e77806 79bf 4d9b 8314 F449c653d87c 07)

FDA Label Image

Indinavir Protocol 035 Figure 7 (C8e77806 79bf 4d9b 8314 F449c653d87c 08)

This appears to be a table or chart showing the results of a study involving Indinavir, Zidovudine, and Lamivudine in regard to cell count change. The table shows the different combinations of the drugs and their respective effects on cell count change over the course of 24 weeks. It is not possible to determine the specific nature of the study or its results without additional context.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.